Industry Trends

A NASEM report for CDER outlines strategies to modernize pharmaceutical manufacturing to ensure reliable access to high-quality drugs, particularly in response to disruptions caused by the pandemic.

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.

The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.

New data comparing past vs. present experience with telemedicine during the pandemic uncovers insight on how patients, doctors, and payers view the market post-COVID.

at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?

Looking Back at 1990-1993.

Ahmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.

Henry McNamara, Senior Vice President and General Manager, Oracle Health Sciences, reviews the lessons that the industry has learned over the last year and looks at what lies ahead for pharma in 2021.

Assessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Disputes over mRNA-related patents are poised to persist.

Industry makes large investments toward public health issues exposed by pandemic.

Looking back at 1986-1989.

Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value.

Agency faces a significant backlog in the US and abroad.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Vaccine manufacturers anticipate significant boosts in output in the coming weeks.

Three changes manufacturers should consider in the wake of COVID-19.

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

R&D on medical treatments lags notable success with vaccines.

Looking back at 1982-1985.

Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.

A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.

Telemedicine is definitely here to stay, but recent study may offer clues on its sustaining power.